Yi-Hsiang Huang

Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC

M. Kudo, N. Nishida, L. Rimassa, 2022, Hepatology communications.

Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?

K. Rau, R. Cheng, S. Rajappa, 2022, World journal of hepatology.

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

M. Kudo, P. Galle, N. Nishida, 2022, Liver international : official journal of the International Association for the Study of the Liver.

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.

M. Kudo, P. Galle, N. Nishida, 2022, European journal of cancer.

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Yuehua Wu, M. Kudo, P. Galle, 2022, Cancers.